Clinical trial NCT00061763: Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
Official title: Phase II Study of Safety & Efficacy of Deferasirox Given for 1 Year in Patients With Chronic Anemias and Transfusional Hemosiderosis Unable to be Treated With Deferoxamine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Beta-thalassemia
Myelodysplastic Syndromes
Fanconi Syndrome
Anemia, Diamond-Blackfan
Anemia, Aplastic
Keywords: beta-thalassemia
iron overload
deferoxamine
Myelodysplastic Syndromes
Fanconi Syndrome
Anemia, Diamond-Blackfan
Anemia, Aplastic
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2003-06-04
Enrollment: 175
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effects of the oral iron chelator Deferasirox on liver iron content after one year of treatment in patients with iron overload from repeated blood transfusions. Beta-thalassemia patients unable to be treated with deferoxamine or patients with rare chronic anemias such as Myelodysplastic Syndrome, Fanconi's Syndrome, Blackfan-Diamond Syndrome, and Pure Red Blood Cell Anemia are eligible for this study. Liver iron content will be measured by liver biopsy at the beginning of the study and after one year of treatment. However, those patients living in the San Francisco/Oakland area may have a SQUID in place of the liver biopsy if the biopsy is not medically possible for them. The SQUID is a non-invasive magnetic means to measure liver iron content.


Eligibility criteria: Inclusion Criteria:

* Beta-thalassemia patients with documented non-compliance to deferoxamine, defined as taking less than 50% of prescribed doses in year prior to study, and having a liver iron content at least 14 mg iron/gm dry weight liver tissue
* Beta-thalassemia patients unable to take deferoxamine because of documented side effects or contra-indication, or documented poor response despite proper compliance, with liver iron content at least 2 mg iron/gm dry weight liver tissue
* Patients with chronic anemias with a liver iron content at least 2 mg/gm dry weight liver tissue.
* Beta-thalassemia or other chronic anemia patients having previously taken deferiprone, provided that they stop the deferiprone at least 28 days before the study and have a liver iron content at least 2 mg/gm dry weight liver tissue.
* All patients: Regular transfusions indicated by a requirement of at least 8 blood transfusions per year.
* Life expectancy of at least one year.

Exclusion Criteria:

* Beta-thalassemia able to be treated with deferoxamine, Sickle Cell Disease or non-transfusional iron overload
* Elevated liver enzymes in the year preceding enrollment
* Active Hepatitis B or Hepatitis C
* HIV seropositivity
* Elevated serum creatinine or significant proteinuria
* History of nephrotic syndrome
* Uncontrolled systemic hypertension
* Fever and other signs/symptoms of infection within 10 days prior to start of the study.
* Presence of clinically relevant cataract or previous history of clinically relevant ocular toxicity related to iron chelation.
* Second or third degree AV block, clinically relevant Q-T interval prolongation, or patients requiring digoxin or other drugs that prolong the Q-T interval.
* Diseases (cardiovascular, renal, hepatic, etc.) that would prevent the patient from undergoing any of the treatment options.
* Psychiatric or additive disorders that would prevent the patient from giving informed consent.
* History of drug or alcohol abuse within the 12 months prior to the study.
* Pregnant or breast feeding patients.
* Patients treated with systemic investigational drugs within 4 weeks or topical investigational drugs within 7 days before the start of teh study.
* Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any drug, such as gastrointestinal disease or major surgery, renal disease, difficulty voiding or urinary obstruction, or impaired pancreatic function.
* Non-compliant or unreliable patients
* Patients unable to undergo any study procedures such as the hearing or eye tests, or the liver echocardiography.
* Patients that would need a dose of Deferasirox less than 125 mg per day.

Primary outcomes:
measure: To evaluate the effects of treatment on the liver iron content(LIC)
Secondary outcomes:
measure: Evaluate tolerability profile
measure: Estimate the absolute and relative change of LIC and total body iron excretion (TBIE) rate
measure: Evaluate the relationship between LIC and potential surrogate markers
measure: Evaluate the relationship between PD and safety variables
Other outcomes:
Locations:
city: Oakland
country: United States
facility: Children's Hospital Oakland
state: California
city: Stanford
country: United States
facility: Stanford Hospital
state: California
city: Arlington Heights
country: United States
facility: Northwest Medical Specialists
state: Illinois
city: Boston
country: United States
facility: Children's Hospital Boston
state: Massachusetts
city: New York
country: United States
facility: Weill Medical College of Cornell University
state: New York
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: